GlassScriptPhysician profile
Michael W Dupre
NPI 1154403491
$2,897.06
in general payments reported to CMS, 2019-2025
16 companies · $619 in 2025
The $619 reported for 2025 was more than what 76% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $684 · 2023: $1,071 · 2024: $523 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $392.19 | 2023-2025 | Vyloy |
| Janssen Biotech, INC. | $375.00 | 2022-2023 | Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $363.64 | 2022-2024 | Lynparza |
| Incyte Corporation | $265.30 | 2023-2024 | Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $225.99 | 2022-2023 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $217.52 | 2024-2025 | Fruzaqla |
| Karyopharm Therapeutics INC. | $126.94 | 2025 | Xpovio |
| Amgen INC. | $126.90 | 2023 | Lumakras |
| Emd Serono, INC. | $125.00 | 2023 | Bavencio |
| Eisai INC. | $121.20 | 2022 | |
| Seagen INC. | $117.32 | 2023 | Adcetris |
| Pfizer INC. | $108.07 | 2025 | |
| Blueprint Medicines Corporation | $104.16 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $85.61 | 2022 | |
| Taiho Oncology, INC. | $74.24 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $67.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dupre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.